524 related articles for article (PubMed ID: 11379826)
1. Clinical trial design issues in schizophrenic research.
Casey DE
J Clin Psychiatry; 2001; 62 Suppl 9():17-20; discussion 21-2. PubMed ID: 11379826
[TBL] [Abstract][Full Text] [Related]
2. Clinical development of atypical antipsychotics: research design and evaluation. Collaborative Working Group on Clinical Trial Evaluations.
J Clin Psychiatry; 1998; 59 Suppl 12():10-6. PubMed ID: 9766614
[TBL] [Abstract][Full Text] [Related]
3. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
4. Dose selection and comparator drugs in schizophrenia research.
Kane JM
J Clin Psychiatry; 2001; 62 Suppl 9():29-32; discussion 33-4. PubMed ID: 11379828
[TBL] [Abstract][Full Text] [Related]
5. FDA perspective on clinical trial design for cardiovascular devices.
Chen E; Sapirstein W; Ahn C; Swain J; Zuckerman B
Ann Thorac Surg; 2006 Sep; 82(3):773-5. PubMed ID: 16928481
[No Abstract] [Full Text] [Related]
6. Reproducibility probability in clinical trials.
Shao J; Chow SC
Stat Med; 2002 Jun; 21(12):1727-42. PubMed ID: 12111908
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients.
Cutler NR
J Clin Psychiatry; 2001; 62 Suppl 5():10-3; discussion 23-4. PubMed ID: 11305842
[TBL] [Abstract][Full Text] [Related]
8. Overhauling clinical trials.
Scott CT; Baker M
Nat Biotechnol; 2007 Mar; 25(3):287-92. PubMed ID: 17344876
[No Abstract] [Full Text] [Related]
9. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
10. International Conference on Harmonisation; choice of control group and related issues in clinical trials; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2001 May; 66(93):24390-1. PubMed ID: 12356096
[TBL] [Abstract][Full Text] [Related]
11. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
[TBL] [Abstract][Full Text] [Related]
12. Evaluating characteristics of patient selection and dropout rates.
Keith SJ
J Clin Psychiatry; 2001; 62 Suppl 9():11-4; discussion 15-6. PubMed ID: 11379825
[TBL] [Abstract][Full Text] [Related]
13. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim.
Laughren T; Levin R
Schizophr Bull; 2006 Apr; 32(2):220-2. PubMed ID: 16079389
[TBL] [Abstract][Full Text] [Related]
14. Introduction: evaluating clinical trial data from schizophrenia research.
Tamminga CA
J Clin Psychiatry; 2001; 62 Suppl 9():3-4. PubMed ID: 11379829
[No Abstract] [Full Text] [Related]
15. Interpretations and conclusions in the clinical trial.
Docherty JP
J Clin Psychiatry; 2001; 62 Suppl 9():40-3; discussion 44-5. PubMed ID: 11379831
[TBL] [Abstract][Full Text] [Related]
16. Drug interaction studies: study design, data analysis, and implications for dosing and labeling.
Huang SM; Temple R; Throckmorton DC; Lesko LJ
Clin Pharmacol Ther; 2007 Feb; 81(2):298-304. PubMed ID: 17259955
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations.
Stroup TS; Alves WM; Hamer RM; Lieberman JA
Nat Rev Drug Discov; 2006 Feb; 5(2):133-46. PubMed ID: 16518380
[TBL] [Abstract][Full Text] [Related]
18. Trial design issues and treatment effect modeling in multi-regional schizophrenia trials.
Chen YF; Wang SJ; Khin NA; Hung HM; Laughren TP
Pharm Stat; 2010; 9(3):217-29. PubMed ID: 20872622
[TBL] [Abstract][Full Text] [Related]
19. Accelerated approval of oncology products: a decade of experience.
Dagher R; Johnson J; Williams G; Keegan P; Pazdur R
J Natl Cancer Inst; 2004 Oct; 96(20):1500-9. PubMed ID: 15494600
[TBL] [Abstract][Full Text] [Related]
20. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
